Bioavailability and pharmacokinetics of oxazepam.
J Sonne, S Loft, M Døssing, A Vollmer-Larsen, K L Olesen, M Victor, F Andreasen, P B Andreasen
Index: Eur. J. Clin. Pharmacol. 35(4) , 385-9, (1988)
Full Text: HTML
Abstract
Six healthy volunteers received oxazepam 15 mg i.v. and orally at an interval of at least one week. The kinetic variables of i.v. oxazepam were: elimination half-life (t1/2 beta) 6.7 h, total clearance (CL) 1.07 ml.min-1.kg-1, volume of distribution (Vc) 0.27 l.kg-1 (0.21-0.49) and volume of distribution at steady-state (Vss) 0.59 l.kg-1. The intravenous disposition of unbound oxazepam was characterized by a clearance of 22.5 ml.min-1.kg-1 and a distribution volume of 12.3 l.kg-1. After oral oxazepam the peak plasma level was reached in 1.7 to 2.8 h. The plasma t1/2 beta at 5.8 h was not significantly different from the i.v. value. Absorption was almost complete, with a bioavailability of 92.8%. Urinary recovery was 80.0 and 71.4% of the dose after intravenous and oral administration, respectively. Renal clearance (CLR) of the glucuronide metabolite was 1.10 ml.min-1.kg-1 (0.98-1.52). Oxazepam was extensively bound to plasma protein with a free fraction of 4.5%.
Related Compounds
Related Articles:
Factors and conditions affecting the glucuronidation of oxazepam.
1993-01-01
[Pharmacol. Toxicol. 73 Suppl 1 , 1-23, (1993)]
(S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7.
1995-02-01
[Pharmacogenetics 5(1) , 43-9, (1995)]
1990-10-01
[J. Pharmacokinet. Biopharm. 18(5) , 423-48, (1990)]
2008-10-01
[Br. J. Clin. Pharmacol. 66(4) , 556-60, (2008)]
The influence of diflunisal on the pharmacokinetics of oxazepam.
1985-09-01
[Br. J. Clin. Pharmacol. 20(3) , 225-34, (1985)]